Which has better earnings & valuation, LMAT or BWAY?

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 8.42 $57.73M $2.71 33.93 Brainsway $52.22M 11.05 $7.57M $0.35 41.11

Does the media refer more to LMAT or BWAY?

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 2 articles in the media. Brainsway's average media sentiment score of 1.21 beat LeMaitre Vascular's score of -0.12 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BWAY or NVCR?

Brainsway has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 11.05 $7.57M $0.35 41.11 NovoCure $655.35M 2.50 -$136.23M -$1.53 N/A

Is BWAY or NVCR more profitable?

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.68% 12.28% 7.75% NovoCure -25.66% -50.82% -16.48%

Does the media prefer BWAY or NVCR?

In the previous week, NovoCure had 17 more articles in the media than Brainsway. MarketBeat recorded 19 mentions for NovoCure and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.21 beat NovoCure's score of 0.01 indicating that Brainsway is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, PLSE or BWAY?

Brainsway has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 5,131.43 -$72.78M -$1.10 N/A Brainsway $52.22M 11.05 $7.57M $0.35 41.11

Does the media favor BFLY or BWAY?

In the previous week, Butterfly Network had 8 more articles in the media than Brainsway. MarketBeat recorded 10 mentions for Butterfly Network and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.21 beat Butterfly Network's score of 0.36 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Butterfly Network 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainsway 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BWAY or EYE?

National Vision has higher revenue and earnings than Brainsway. National Vision is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 11.05 $7.57M $0.35 41.11 National Vision $1.99B 0.68 $29.60M $0.57 29.44

Does the media refer more to BWAY or EYE?

In the previous week, Brainsway had 1 more articles in the media than National Vision. MarketBeat recorded 2 mentions for Brainsway and 1 mentions for National Vision. Brainsway's average media sentiment score of 1.21 beat National Vision's score of 1.02 indicating that Brainsway is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Vision 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainsway (BWAY) Competitors

$14.39 +0.01 (+0.07%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$14.38 -0.01 (-0.10%)

As of 04:08 AM Eastern

Compare

BWAY vs. LMAT, NVCR, PLSE, BFLY, and EYE

Should you buy Brainsway stock or one of its competitors? MarketBeat compares Brainsway with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainsway include LeMaitre Vascular (LMAT), NovoCure (NVCR), Pulse Biosciences (PLSE), Butterfly Network (BFLY), and National Vision (EYE). These companies are all part of the "medical equipment" industry.

How does Brainsway compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

LeMaitre Vascular currently has a consensus target price of $112.60, suggesting a potential upside of 22.46%. Brainsway has a consensus target price of $16.00, suggesting a potential upside of 11.19%. Given LeMaitre Vascular's higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, LeMaitre Vascular and LeMaitre Vascular both had 2 articles in the media. Brainsway's average media sentiment score of 1.21 beat LeMaitre Vascular's score of -0.12 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LeMaitre Vascular has a net margin of 24.35% compared to Brainsway's net margin of 15.68%. LeMaitre Vascular's return on equity of 15.36% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Brainsway	15.68%	12.28%	7.75%

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.42	$57.73M	$2.71	33.93
Brainsway	$52.22M	11.05	$7.57M	$0.35	41.11

LeMaitre Vascular has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

LeMaitre Vascular beats Brainsway on 10 of the 15 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

Brainsway (NASDAQ:BWAY) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Brainsway has a net margin of 15.68% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 12.28% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
NovoCure	-25.66%	-50.82%	-16.48%

Brainsway has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.05	$7.57M	$0.35	41.11
NovoCure	$655.35M	2.50	-$136.23M	-$1.53	N/A

Brainsway has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Brainsway presently has a consensus price target of $16.00, indicating a potential upside of 11.19%. NovoCure has a consensus price target of $26.86, indicating a potential upside of 90.07%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, NovoCure had 17 more articles in the media than Brainsway. MarketBeat recorded 19 mentions for NovoCure and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.21 beat NovoCure's score of 0.01 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Brainsway beats NovoCure on 11 of the 16 factors compared between the two stocks.

How does Brainsway compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Brainsway has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,131.43	-$72.78M	-$1.10	N/A
Brainsway	$52.22M	11.05	$7.57M	$0.35	41.11

In the previous week, Brainsway had 2 more articles in the media than Pulse Biosciences. MarketBeat recorded 2 mentions for Brainsway and 0 mentions for Pulse Biosciences. Brainsway's average media sentiment score of 1.21 beat Pulse Biosciences' score of 0.00 indicating that Brainsway is being referred to more favorably in the news media.

Company	Overall Sentiment
Pulse Biosciences	Neutral
Brainsway	Positive

Brainsway has a net margin of 15.68% compared to Pulse Biosciences' net margin of 0.00%. Brainsway's return on equity of 12.28% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
Brainsway	15.68%	12.28%	7.75%

Pulse Biosciences currently has a consensus price target of $30.67, suggesting a potential upside of 18.18%. Brainsway has a consensus price target of $16.00, suggesting a potential upside of 11.19%. Given Pulse Biosciences' higher probable upside, equities research analysts clearly believe Pulse Biosciences is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Brainsway beats Pulse Biosciences on 10 of the 15 factors compared between the two stocks.

How does Brainsway compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Butterfly Network has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Butterfly Network currently has a consensus price target of $5.56, indicating a potential downside of 27.67%. Brainsway has a consensus price target of $16.00, indicating a potential upside of 11.19%. Given Brainsway's stronger consensus rating and higher possible upside, analysts clearly believe Brainsway is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Brainsway has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$102.92M	19.03	-$77.06M	-$0.30	N/A
Brainsway	$52.22M	11.05	$7.57M	$0.35	41.11

In the previous week, Butterfly Network had 8 more articles in the media than Brainsway. MarketBeat recorded 10 mentions for Butterfly Network and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.21 beat Butterfly Network's score of 0.36 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Butterfly Network	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

37.8% of Butterfly Network shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Brainsway has a net margin of 15.68% compared to Butterfly Network's net margin of -73.63%. Brainsway's return on equity of 12.28% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Brainsway	15.68%	12.28%	7.75%

Summary

Brainsway beats Butterfly Network on 9 of the 15 factors compared between the two stocks.

How does Brainsway compare to National Vision?

Brainsway (NASDAQ:BWAY) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Brainsway currently has a consensus target price of $16.00, suggesting a potential upside of 11.19%. National Vision has a consensus target price of $30.08, suggesting a potential upside of 79.28%. Given National Vision's higher probable upside, analysts plainly believe National Vision is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

Brainsway has a net margin of 15.68% compared to National Vision's net margin of 2.31%. Brainsway's return on equity of 12.28% beat National Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.68%	12.28%	7.75%
National Vision	2.31%	6.41%	2.81%

30.1% of Brainsway shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 2.4% of National Vision shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

National Vision has higher revenue and earnings than Brainsway. National Vision is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	11.05	$7.57M	$0.35	41.11
National Vision	$1.99B	0.68	$29.60M	$0.57	29.44

Brainsway has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, National Vision has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, Brainsway had 1 more articles in the media than National Vision. MarketBeat recorded 2 mentions for Brainsway and 1 mentions for National Vision. Brainsway's average media sentiment score of 1.21 beat National Vision's score of 1.02 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Vision	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Brainsway beats National Vision on 11 of the 16 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$576.54M	$8.08B	$6.44B	$12.38B
Dividend Yield	N/A	2.59%	2.69%	5.83%
P/E Ratio	41.12	15.24	24.66	23.99
Price / Sales	11.05	6.99	527.00	106.82
Price / Cash	61.42	16.83	44.82	54.51
Price / Book	7.70	3.21	10.75	6.50
Net Income	$7.57M	$226.25M	$3.56B	$336.88M
7 Day Performance	-0.14%	-1.89%	1.00%	-0.14%
1 Month Performance	-4.70%	-3.72%	0.43%	0.77%
1 Year Performance	134.75%	-1.12%	29.69%	28.49%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	3.2542 of 5 stars	$14.39 +0.1%	$16.00 +11.2%	+150.5%	$576.54M	$52.22M	41.12	120	Positive News Gap Down
LMAT LeMaitre Vascular	4.6299 of 5 stars	$93.51 +1.7%	$112.60 +20.4%	+10.3%	$2.14B	$249.60M	34.50	490
NVCR NovoCure	3.0373 of 5 stars	$17.60 flat	$27.29 +55.0%	-14.9%	$2.04B	$655.35M	N/A	1,605	Analyst Revision
PLSE Pulse Biosciences	1.9394 of 5 stars	$25.49 -1.7%	$30.67 +20.3%	+67.5%	$1.77B	$350K	N/A	140
BFLY Butterfly Network	1.2759 of 5 stars	$5.72 +1.5%	$5.56 -2.7%	+275.1%	$1.46B	$97.61M	N/A	460	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. LMAT, NVCR, PLSE, BFLY, and EYE

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to NovoCure?

Summary

How does Brainsway compare to Pulse Biosciences?

Summary

How does Brainsway compare to Butterfly Network?

Summary

How does Brainsway compare to National Vision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. LMAT, NVCR, PLSE, BFLY, and EYE

How does Brainsway compare to LeMaitre Vascular?

Do analysts rate LMAT or BWAY?

Does the media refer more to LMAT or BWAY?

Is LMAT or BWAY more profitable?

Which has better earnings & valuation, LMAT or BWAY?

Which has more risk and volatility, LMAT or BWAY?

Do institutionals and insiders have more ownership in LMAT or BWAY?

Summary

How does Brainsway compare to NovoCure?

Is BWAY or NVCR more profitable?

Which has better earnings and valuation, BWAY or NVCR?

Which has more risk and volatility, BWAY or NVCR?

Do analysts rate BWAY or NVCR?

Does the media prefer BWAY or NVCR?

Do insiders and institutionals believe in BWAY or NVCR?

Summary

How does Brainsway compare to Pulse Biosciences?

Do institutionals and insiders have more ownership in PLSE or BWAY?

Which has more volatility & risk, PLSE or BWAY?

Which has better valuation & earnings, PLSE or BWAY?

Does the media refer more to PLSE or BWAY?

Is PLSE or BWAY more profitable?

Do analysts recommend PLSE or BWAY?

Summary

How does Brainsway compare to Butterfly Network?

Which has more risk and volatility, BFLY or BWAY?

Do analysts prefer BFLY or BWAY?

Which has higher valuation & earnings, BFLY or BWAY?

Does the media favor BFLY or BWAY?

Do insiders & institutionals have more ownership in BFLY or BWAY?

Is BFLY or BWAY more profitable?

Summary

How does Brainsway compare to National Vision?

Do analysts rate BWAY or EYE?

Is BWAY or EYE more profitable?

Do insiders & institutionals hold more shares of BWAY or EYE?

Which has better earnings and valuation, BWAY or EYE?

Which has more volatility & risk, BWAY or EYE?

Does the media refer more to BWAY or EYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools